Psychotropic medication use before and during COVID-19: a population-wide study
Background: The coronavirus disease 2019 (COVID-19) pandemic and public health
measures that took place have led to concerns regarding mental health and receipt of …
measures that took place have led to concerns regarding mental health and receipt of …
[HTML][HTML] The neuropsychiatric manifestations of COVID-19: Interactions with psychiatric illness and pharmacological treatment
The recent outbreak of the corona virus disease (COVID-19) has had major global impact.
The relationship between severe acute respiratory syndrome coronavirus (SARS-CoV-2) …
The relationship between severe acute respiratory syndrome coronavirus (SARS-CoV-2) …
[HTML][HTML] Hydroxychloroquine/chloroquine as therapeutics for COVID-19: truth under the mystery
Y Chen, MX Li, GD Lu, HM Shen… - International Journal of …, 2021 - ncbi.nlm.nih.gov
The outbreak of coronavirus disease-19 (COVID-19) caused by severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) has rapidly evolved into a global pandemic. One …
syndrome coronavirus 2 (SARS-CoV-2) has rapidly evolved into a global pandemic. One …
[PDF][PDF] Aminoquinolines against coronavirus disease 2019 (COVID-19): chloroquine or hydroxychloroquine
Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2), continues to spread rapidly across China. As of 7 March 2020 …
coronavirus 2 (SARS-CoV-2), continues to spread rapidly across China. As of 7 March 2020 …
A pharmacological perspective of chloroquine in SARS-CoV-2 infection: An old drug for the fight against a new coronavirus?
TJ Oscanoa, R Romero-Ortuno, A Carvajal… - International journal of …, 2020 - Elsevier
ABSTRACT The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) is having serious consequences on …
respiratory syndrome coronavirus 2 (SARS-CoV-2) is having serious consequences on …
Safety of psychotropic medications in people with COVID-19: evidence review and practical recommendations
Background: The novel coronavirus pandemic calls for a rapid adaptation of conventional
medical practices to meet the evolving needs of such vulnerable patients. People with …
medical practices to meet the evolving needs of such vulnerable patients. People with …
Hydroxychloroquine and chloroquine: a potential and controversial treatment for COVID-19
L Zou, L Dai, X Zhang, Z Zhang, Z Zhang - Archives of pharmacal research, 2020 - Springer
A novel coronavirus, later named SARS-CoV-2, was first reported in China in December
2019 and subsequently widely identified in the United States, Japan, South Korea, France …
2019 and subsequently widely identified in the United States, Japan, South Korea, France …
CNS penetration of potential anti-COVID-19 drugs
In the context of the current COVID-19 pandemic, the ability of coronaviruses to enter the
CNS and cause neurological deficits has been largely overlooked despite the fact that the …
CNS and cause neurological deficits has been largely overlooked despite the fact that the …
Repurposing of CNS drugs to treat COVID-19 infection: targeting the sigma-1 receptor
K Hashimoto - European archives of psychiatry and clinical …, 2021 - Springer
The novel coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2). The escalating number of SARS-CoV-2-infected …
syndrome coronavirus 2 (SARS-CoV-2). The escalating number of SARS-CoV-2-infected …
Efetividade e toxicidade da cloroquina e da hidroxicloroquina associada (ou não) à azitromicina para tratamento da COVID-19. O que sabemos até o momento?
CR Menezes, C Sanches… - Journal of Health & …, 2020 - unichristus.emnuvens.com.br
Objetivos: identificar as evidências científicas existentes até o presente momento sobre a
efetividade do uso da cloroquina, da hidroxicloroquina associada (ou não) à azitromicina …
efetividade do uso da cloroquina, da hidroxicloroquina associada (ou não) à azitromicina …